Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumetinib in MET-altered Advanced NSCLC (Ib/II)
CTR20190900Phase 2Active
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glumetinib in non-small cell lung cancer (NSCLC), lung sarcomatoid carcinoma (PSC), sponsored by Shanghai Institute of Materia Medica. Started May 2019; status: active.
02
Drugs
glumetinib
03
Conditions
non-small cell lung cancer (NSCLC)lung sarcomatoid carcinoma (PSC)
Beyond the preview
Go deeper on CTR20190900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190900.